- Home
- PEPG vs IVVD Comparison
PEPG vs IVVD Comparison
Compare PEPG & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEPG
- IVVD
- Stock Information
- Founded
- PEPG 2018
- IVVD 2020
- Country
- PEPG United States
- IVVD United States
- Employees
- PEPG N/A
- IVVD N/A
- Industry
- PEPG Biotechnology: Pharmaceutical Preparations
- IVVD Biotechnology: Pharmaceutical Preparations
- Sector
- PEPG Health Care
- IVVD Health Care
- Exchange
- PEPG Nasdaq
- IVVD Nasdaq
- Market Cap
- PEPG 317.6M
- IVVD 377.4M
- IPO Year
- PEPG 2022
- IVVD 2021
- Fundamental
- Price
- PEPG $4.91
- IVVD $1.68
- Analyst Decision
- PEPG Strong Buy
- IVVD Strong Buy
- Analyst Count
- PEPG 6
- IVVD 5
- Target Price
- PEPG $9.17
- IVVD $6.11
- AVG Volume (30 Days)
- PEPG 676.6K
- IVVD 4.2M
- Earning Date
- PEPG 11-06-2025
- IVVD 11-06-2025
- Dividend Yield
- PEPG N/A
- IVVD N/A
- EPS Growth
- PEPG N/A
- IVVD N/A
- EPS
- PEPG N/A
- IVVD N/A
- Revenue
- PEPG N/A
- IVVD $50,039,000.00
- Revenue This Year
- PEPG N/A
- IVVD $102.11
- Revenue Next Year
- PEPG N/A
- IVVD $151.51
- P/E Ratio
- PEPG N/A
- IVVD N/A
- Revenue Growth
- PEPG N/A
- IVVD 332.71
- 52 Week Low
- PEPG $0.88
- IVVD $0.35
- 52 Week High
- PEPG $6.85
- IVVD $2.74
- Technical
- Relative Strength Index (RSI)
- PEPG 56.79
- IVVD 50.79
- Support Level
- PEPG $4.05
- IVVD $1.39
- Resistance Level
- PEPG $4.89
- IVVD $1.65
- Average True Range (ATR)
- PEPG 0.40
- IVVD 0.22
- MACD
- PEPG -0.07
- IVVD -0.05
- Stochastic Oscillator
- PEPG 51.90
- IVVD 31.31
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.